Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137230 | 1.00 | CACNA1I (0.59) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2135052 | 0.94 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2135048 | 0.94 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2138192 | 0.94 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL21823927 | 0.89 | CACNA1I (0.48) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2137052 | 0.88 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2137047 | 0.88 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2143533 | 0.88 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2143523 | 0.88 | CACNA1I (0.61) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 | |
| SCHEMBL2135196 | 0.87 | CACNA1I (0.60) | CACNA1ICACNA1GCACNA1HCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | CACNA1I 1/4885CACNA1G 2/4885CACNA1H 3/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | CACNA1I 1/4885CACNA1G 2/4885CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.